In relation to breast cancer, galectin-3 has a described role in enhancing metastatic disease through resistance to the products of inducible nitric oxide synthase and through its bcl-2-like anti-apoptotic properties [66]. The gene discussed is LGALS3; the disease is metastatic neoplasm.